|
Jun 30
|
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
|
|
Jun 27
|
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 2.5% for Week
|
|
Jun 26
|
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
|
|
Jun 26
|
General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls
|
|
Jun 25
|
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
|
|
Jun 23
|
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
|
|
Jun 17
|
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
|
|
Jan 13
|
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
|
|
Aug 28
|
Adaptimmune to Participate in Two Bank Conferences this September
|
|
Aug 15
|
Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago
|
|
Jul 25
|
Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?
|
|
Jun 12
|
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
|
|
May 15
|
Adaptimmune Reports Q1 2024 Financial and Business Updates
|
|
May 15
|
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
|
|
May 1
|
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
|
|
Apr 15
|
Adaptimmune (ADAP) Down on End of Collaboration With Roche
|
|
Apr 12
|
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
|
|
Apr 12
|
Roche, Adaptimmune part ways on cell therapy research
|
|
Mar 27
|
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
|
|
Mar 8
|
Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|